Ohr Pharmaceutical (OTC BB: OHRP) Data Review Supports Strong Potential of EVIZON(TM) for Wet AMD (Marketwire via Yahoo! Finance)
November 23rd, 2009
DOVER, DE–(Marketwire – 11/23/09) – As part of its drug pipeline Ohr Pharmaceutical (OTC.BB: OHRP – News ) is developing a wet AMD (Macular Degeneration) therapy, based on technology acquired from Genaera Liquidating Trust. This novel therapeutic agent (EVIZON(TM)) has demonstrated the improvement or stabilization in vision in more than 100 subjects with wet AMD. Patients (wet AMD subjects …
Original post by macular degeneration – Google News
(click on the author/publication link above to see full post)